Cellular precOnditioning for Post-Surgical Myocardial Ischemic Complications - Observational Study (COSMIC)
The goal of this observational study is to collect health data on people who are at high risk of having heart complications and are having a surgery that is not on the heart. The main questions it aims to answer are:
- Is this study feasible in terms of recruiting enough people to participate in this study?
- How often do heart complications happen in people who are at high risk of heart complications and are having a surgery that is not on the heart?
Participants will have their usual care and will also be asked to:
- Have extra bloodwork done
- Complete some surveys
- Have two echocardiograms (ultrasounds of the heart)
- Continue to follow-up with the research team for one year after their surgery
Researchers will compare how often heart complications occur in this high risk population to a future study where participants will receive stem cells before their surgery.
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Meredith Conboy, MSc
- Phone Number: 73800 613-737-8899
- Email: mconboy@ohri.ca
Study Contact Backup
- Name: Manoj M Lalu, MD, PhD
- Phone Number: 75083 613-737-8899
- Email: mlalu@toh.ca
Study Locations
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H 8L6
- Recruiting
- The Ottawa Hospital
-
Principal Investigator:
- Manoj M Lalu, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
A participant must meet all 5 inclusion criteria to be eligible:
- Referred for elective intermediate to high risk noncardiac surgery as defined by the American Heart Association guidelines (e.g., intrathoracic, open intraabdominal, or open vascular surgery)
- 45 years of age or older
- Revised cardiac risk index ≥ 2
- NT-proBNP level of ≥ 200 pg/mL
- Able to provide informed consent
Exclusion Criteria:
- Experience an acute coronary syndrome, myocardial infarction, heart failure, or stroke within preceding 3 months
- Coronary revascularization anticipated during the study period
- Severe mitral/aortic valve stenosis
- Evidence of clinically significant arrhythmia in last three months.
- Major surgical procedure in previous 3 months
- History of malignancy requiring surgery, chemotherapy, immunotherapy, or radiation within previous 5 years
- Ongoing malignancy requiring surgical resection
- Women who are pregnant, breastfeeding, or of childbearing potential who are unable to use a medically acceptable form of contraception throughout the study
- Received any experimental cell therapy previously
- Unable to provide written informed consent
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Feasibility of Participant Recruitment
Time Frame: 1 year
|
Our primary outcome is the feasibility of participant recruitment.
This will be determined by measurements of recruitment efficiency: 1) proportion of potentially eligible participants that are successfully screened; 2) proportion of participants successfully screened who do not enroll (reason for failure to enroll will be recorded).
|
1 year
|
|
Baseline Frequency of adverse events and serious adverse events
Time Frame: 1 year
|
To determine the baseline frequency of adverse events and serious adverse events in this high risk population
|
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of life of participants
Time Frame: 1 year
|
The EQ-5D-5L questionnaire will be used.
This questionnaire measures quality of life using five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression.
Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems.
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Manoj M Lalu, MD, PhD, The Ottawa Hospital Research Institute, The Ottawa Hospital, University of Ottawa
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 20220330-01H
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.